Bare Financial Services’s Definium Therapeutics DFTX Stock Holding History

Bare Financial Services’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$685	Buy	+18	New	+$759	﹤0.01%	1624

Other funds holding DFTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bare Financial Services's DFTX Position: Q3 2026 in Review

Bare Financial Services opened a new position in Definium Therapeutics (DFTX) in Q3 2026: 18 shares worth $685. The stake represents ﹤0.01% of the portfolio and ranks #1624 among its holdings.

159 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Bare Financial Services held 18 shares of Definium Therapeutics worth $685 as of Q3 2026.
Definium Therapeutics was a new Bare Financial Services position in Q3 2026.
Definium Therapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q3 2026, its #1624 holding.
159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Bare Financial Services's 13F filing for Q3 2026, filed 4 Nov 2026.